Background:
Over 80,000 cases of clade 2b Mpox were reported in 2022 outside traditionally endemic African countries. The transmission and features of clade 2b Mpox differ from clade 1, requiring systematic clinical characterisation.
Methods:
MOSAIC is a cohort study of clinical and virological outcomes of patients with laboratory-confirmed Mpox in 10 European countries started in May 2022. Administration of tecovirimat is at the discretion of the patient’s treating clinician under routine care and subject to drug availability.The primary outcome is time to lesion resolution from the date of a positive test result (or the date of treatment start, if treatment was delayed) through D14 without any serious complications. Results presented here were obtained from Kaplan-Meier estimates.Secondary outcomes presented are virologic status at D14, and clinical status at D28 using a four-point scale: all lesions resolved and no serious complications; active lesions and no serious complications; hospitalized due to a serious mpox complication; death.We selected 10 non-tecovirimat-treated patients with oropharyngeal and anal swabs, and plasma samples (except one) available at inclusion and D14. qPCR was performed using a G2R target of MXPV (Ct value >40 was considered as negative).
Results:
We report on the first 122 cases enrolled by November 15th 2022 (94 recruited in France, 24 in Switzerland, 4 in the UK), 98% male, median [IQR] age 35 [29, 44], of whom 21 received tecovirimat. Patients presented ~1 week after symptoms onset. A third of patients treated with tecovirimat had lesions or complications remaining at D28 (see table).The 10 patients with virologic data had a median [range] qPCR baseline Ct values of 39 [28, 40], 37 [32, 40], and 24 [17, 40] for oropharyngeal, plasma and anal samples, respectively. All plasma and oropharyngeal samples were negative at D14; 3 patients had positive anal samples at D14 with all lesions resolved without serious complications.
Conclusions:
MOSAIC is an international study describing characteristics and outcomes of Clade 2b Mpox; it does not support direct comparison between tecovirimat-treated and non-treated patients. Lesions and symptoms resolved within 28 days in most uncomplicated cases with supportive treatment without hospitalisation. A higher proportion of patients presented with complications at baseline in the tecovirimat-treated group. There was also a lower proportion of patients in this group whose lesions had resolved with no serious complications at D28.
Baseline characteristics and outcomes ![]()